We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
표시할 이벤트가 없습니다.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 05. 27. | 장 마감 후 (AMC) | — | — | — | — | — | 예정 |
Rating & price-target changes
표시할 리서치 액션이 없습니다.
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
표시할 보유 데이터가 없습니다.
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
InnoCan Pharma Corporation operates as a pharmaceutical technology company in United States, Canada, Europe, and internationally. The company operates through two segments, Online sales and Other Operations. The company develops a cannabidiol (CBD)-loaded liposome drug delivery platform (CBD-LPT), which is in the preclinical trial phase to treat chronic pain management for human and veterinary health sectors. It also offers a pain-relieving topical composition, as well as compositions for the treatment of hemorrhoid, psoriasis of the scalp, vaginal atrophy, and diabetic symptoms. The company is also involved in development, manufacture, and marketing of cosmetic products. InnoCan Pharma Corporation was founded in 2017 and is headquartered in Calgary, Canada.
Stored first · Google News · Yahoo Finance (English)
Innocan Pharma Posts Strong Q1 2026 Results*, With Revenue Surging 29.7% to US$6.47M - Yahoo Finance
Innocan Pharma Posts Strong Q1 2026 Results*, With Revenue Surging 29.7% to US$6.47M Yahoo Finance
Press Release: Innocan Pharma Posts Strong Q1 2026 Results*, With Revenue Surging 29.7% to US$6.47M - Moomoo
Press Release: Innocan Pharma Posts Strong Q1 2026 Results*, With Revenue Surging 29.7% to US$6.47M Moomoo
Innocan Pharma LPT-CBD is featured in Pain Medicine News - PR Newswire
Innocan Pharma LPT-CBD is featured in Pain Medicine News PR Newswire
Innocan Pharma Announces Closing of Additional Debenture
Innocan Pharma Announces Offering of an Additional Debenture to Tamar Innovest
Innocan Pharma Reports 2025 Financial Results, with Revenues at US $26.6M - Yahoo Finance
Innocan Pharma Reports 2025 Financial Results, with Revenues at US $26.6M Yahoo Finance